Position in KALV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$20,558,769
+$7,617,774 QoQ
Shares Held
1,021,300
+27.5% QoQ
Ownership
1.92%
of shares outstanding
% of Portfolio
5.84%
of 13F equity value
Holder Rank
#19
of 182 holders
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in KALV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Elmind Capital, LP holds $331,213,880 across 30 Biotechnology names. KALV ranks #5 (6.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
1,170,740 | $45,061,782 | |
| 2 | SNDX |
Syndax Pharmaceuticals Inc
|
1,855,000 | $43,332,800 | |
| 3 | CLDX |
Celldex Therapeutics, Inc.
|
865,000 | $27,437,800 | |
| 4 | CTMX |
CytomX Therapeutics, Inc.
|
4,550,000 | $21,385,000 | |
| 5 | KALV |
KalVista Pharmaceuticals, Inc.
This page
|
1,021,300 | $20,558,769 | |
| 6 | CGON |
CG Oncology, Inc.
|
291,800 | $19,749,024 | |
| 7 | VERA |
Vera Therapeutics, Inc.
|
482,500 | $19,410,975 | |
| 8 | PCVX |
Vaxcyte, Inc.
|
316,500 | $18,391,815 |
All Filings in KALV
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $20,558,769 | 1,021,300 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $12,940,995 | 801,300 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||